Table A2.
Parkinson’s disease patients firstly treated with CLI, DBS as second treatment—single center.
| Case | Sex | Age at PD Diagnosis (Years) | Age at Initiation Initial Treatment (Years) | Interval between Treatments (Months) | Pre-DBS UPDRS-III Off/On Medication § | LEDD Pre-First/Pre-Second/Post-Second Treatment | DBS Target | Initial Effect of First Treatment | Indication(s) for Second Treatment | Effect of Second Treatment DBS | CLI Treatment Continued | Adverse Effects of Both Treatments | Patient Satisfied after 2nd Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J | M | 42 | 48 | 102 | 43 */8 * | UA/3451/1323 | R/L STN | Excellent | MFD | No change | Yes | CLI: site infected, SI, hallucinations | Yes |
| K | M | 47 | 64 | 39 | 59 */34 * | UA/1616/1137 | R/L STN | Good | MFD, GI | Some improvement | Yes | DBS: hematoma at stimulator site | Yes |
| L | M | 45 | 53 | 21 | 40/8 | 1700/3110/1467 | R/L STN | Little | MFD, anxiety | Large improvement | Yes | CLI: anxiety DBS: temporary SI |
Yes |
| M | M | 37 | 47 | 44 | 49 */21 * | 1263/2830/1015 | R/L STN | Poor | MFD | Some improvement | No | None reported | No |
| N | M | 55 | 61 | 35 | 53 */16 * | 1849/2720/1474 | R/L STN | Good | MF | Some deterioration | Yes | None reported | No |
| O | M | 42 | 48 | 89 | 68 */36 * | 2350/2799/2202 | R/L STN | Good | MFD, off phase dystonia and GI | Some improvement | Yes | None reported | Yes |
| P | M | 64 | 74 | 18 | 66 */24 * | 2148/1864/613 | R/L STN | Good | MFD, sleep disorders, freezing | UA | No | DBS: intracranial hemorrhage | UA |
| Q | M | 53 | 58 | 84 | 50 */17 * | 2250/1719/902 | R/L STN | Excellent | MFD, freezing | Some improvement | Yes | None reported | No |
| R | M | 54 | 67 | 48 | 31 */14 * | UA/1814/383 | R/L STN | Excellent | Pain, PNP | Some improvement | No | CLI: PNP | Yes |
| S | M | 56 | 61 | 29 | 46 */22 * | UA/2557/375 | R/L STN | Good | Discomfort of CLI system, MF, akathisia | Large improvement | No | CLI: PNP | Yes |
| Mean/Total | 50 | 58 | 51 |
1927/2448/1089
(n = 6/n = 10/n = 10) |
7 improved, 1 no change, 1 deteriorated, 1 UA | 6 satisfied, 3 unsatisfied, 1 UA | |||||||
BI: balance impairment; CLI: continuous levodopa/carbidopa infusion; DBS: deep brain stimulation; F: female; GI: gait impairment; LEDD: levodopa equivalent daily dose; M: male; MF: motor fluctuations; MFD: motor fluctuations and dyskinesias; PD: Parkinson’s disease; PNP: polyneuropathy; R/L: right/left; SI: speech impairment; STN: subthalamic nucleus; UA: unavailable; UPDRS: Unified Parkinson’s Disease Rating Scale, part III (*: MDS-UPDRS-III (post 2013) was used). § Pre and post CLI UPDRS-III were not available for direct comparison.